Status:
UNKNOWN
Evaluation of CYP2C9 Activity
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
United States - Israel Binational Science Foundation
Conditions:
Healthy
Eligibility:
All Genders
20-50 years
Phase:
NA
Brief Summary
The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9. The purpose of the present study is: 1. ...
Eligibility Criteria
Inclusion
- Age range of 20-50 years old
- Absence of significant disease states
Exclusion
- The presence of significant disease states
- The use of drugs (including birth control pills)
Key Trial Info
Start Date :
August 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT00162461
Start Date
August 1 1998
End Date
December 1 2020
Last Update
June 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel